drugset / Trial / NCT05184764
Study Evaluating Safety, Tolerability, and Efficacy of Intravenous AP-SA02 in Subjects With S. Aureus Bacteremia
Phase 1/2
Completed
56 enrolled
Armata Pharmaceuticals, Inc.
United States Department of Defense · collab
RandomizedParallel-groupTriple-blindTreatment
Summary
Phase 1b/2a, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Escalation Study of the Safety, Tolerability, and Efficacy of Intravenous AP SA02 as an Adjunct to Best Available Antibiotic Therapy Compared to Best Available Antibiotic Therapy Alone for the Treatment of Adults With Bacteremia Due to Staphylococcus aureus
Timeline
- Start
- 2022-04-26
- Primary completion
- 2024-11-07
- Completion
- 2025-01-14
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AP-SA02 | Other / unclassified | — | Intravenous |